Sysmex Corporation

Sysmex Corporation is a Japanese healthcare and medical-technology company headquartered in Kobe, Hyogo Prefecture. Its principal business is the development, manufacture, sale, and support of clinical laboratory systems used to examine blood, urine, and other biological specimens. The company’s portfolio combines analytical instruments, diagnostic reagents, software, service, and associated laboratory solutions rather than relying on equipment sales alone. The business originated in 1968 as TOA Medical Electronics, a medical-electronics operation associated with TOA Corporation. The Sysmex brand was introduced in 1978, initially gaining recognition through hematology analyzers. Hematology became the company’s defining field and remains a central part of its identity, although the business has expanded into adjacent areas such as urinalysis, coagulation testing, and other forms of in-vitro diagnostic testing. Sysmex’s products are used by hospitals, clinical laboratories, public-health facilities, and other healthcare organizations that require automated, repeatable analysis of patient specimens. A major element of Sysmex’s model is the integration of instruments with dedicated reagents and laboratory information capabilities. This approach supports recurring reagent demand and allows the company to provide complete testing workflows, including analysis, data management, maintenance, and technical support. Its product families include automated hematology analyzers, urinalysis systems, coagulation analyzers, reagents, and software or information-technology solutions for laboratory operations. The company is also involved, through associated activities, in the sale of extracorporeal diagnostic agents and the import and sale of medical devices. The company adopted the corporate name Sysmex Corporation in 1998, reflecting the strength of the Sysmex name in the market. From its Japanese base, Sysmex developed a broad international presence with offices, factories, subsidiaries, and regional branches across Asia, Europe, North America, and Oceania. Its overseas markets include the United States, Germany, the United Kingdom, China, Singapore, Canada, Australia, and New Zealand, among others. The company also exports to more than 190 destinations. As of March 31, 2025, the reported corporate structure comprised 79 global subsidiaries and one associated company, while overseas sales represented 86.7% of total sales. Sysmex positions itself as a specialist in laboratory diagnostics, emphasizing analytical reliability, automation, workflow efficiency, and long-term customer support. Its customers typically depend on high instrument availability and consistent test performance, making service infrastructure, reagent compatibility, and software integration important parts of the brand proposition. The company’s international scale allows it to serve both domestic and overseas healthcare systems, while its historical concentration in hematology gives it a distinctive identity within the broader in-vitro diagnostics industry. Today, Sysmex remains an active global medical-technology brand. Its business scope extends beyond individual analyzers to connected laboratory ecosystems and diagnostic consumables. The company’s continuing development reflects the wider movement in clinical laboratories toward automation, standardized testing, higher throughput, and digitally managed workflows.

Sysmex traces its origins to 1968, when it was established as TOA Medical Electronics in Japan. The company entered a period in which electronic measurement technologies were transforming clinical laboratories. Automated instruments could process more specimens with greater consistency than manual methods, creating opportunities for specialized manufacturers able to combine electronics, measurement science, reagents, and laboratory know-how. The company developed its reputation in hematology, especially through automated blood-cell analysis. Hematology analyzers became a foundation for routine hospital testing because they could support high-volume complete blood counts and provide increasingly detailed information about blood-cell populations. Sysmex’s growth was therefore linked both to the expansion of clinical testing and to the movement of laboratories toward automation and standardized workflows. As the business expanded outside Japan, Sysmex became the principal international brand. The name was used across diagnostic instruments, reagents, service activities, and overseas operations, helping the company present a consistent identity in multiple markets. In 2008, TOA Medical Electronics formally changed its corporate name to Sysmex Corporation. The change reflected the fact that the Sysmex name had become the company’s established global identity rather than representing a narrow product line. During its international expansion, Sysmex developed sales and service capabilities across Asia-Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its international model has combined wholly owned subsidiaries, local commercial organizations, distributors, and partnerships. Because diagnostic laboratories depend on continuing supplies of compatible reagents, calibration, maintenance, software updates, and technical support, the company’s installed base and service infrastructure have been important parts of its competitive position. The company broadened its portfolio beyond hematology. Urinalysis became an important adjacent field, with automated systems designed to analyze urine chemistry, particles, and sediment. Hemostasis and coagulation added another major laboratory discipline, serving testing related to clotting disorders, anticoagulation management, surgery, and other clinical needs. Sysmex also entered or expanded in clinical flow cytometry, immunochemistry, laboratory automation, information systems, and specialized diagnostic testing. Strategic relationships supported this diversification. Sysmex and Siemens Healthineers established a global strategic alliance in laboratory diagnostics, allowing the companies to combine selected complementary capabilities and commercial reach while retaining their distinct corporate identities. Sysmex also expanded its specialized hemostasis offering through the acquisition of HYPHEN BioMed, a French company associated with reagents and systems for specialized coagulation testing. Product development has increasingly emphasized complete laboratory environments rather than stand-alone analyzers. Sysmex has supplied combinations of instruments, reagents, automation, information-management software, connectivity, and service. These systems are intended to address pressure on laboratories to increase capacity, reduce manual steps, improve traceability, and make more effective use of skilled staff. The company has also pursued digital connectivity and data-oriented approaches as healthcare providers seek greater standardization across networks of laboratories. Today, Sysmex is an active publicly listed Japanese diagnostics company with a global customer base. Hematology remains its best-known field, while urinalysis, hemostasis, automation, software, flow cytometry, immunochemistry, and specialized testing contribute to a broader clinical-laboratory portfolio. Its history is therefore one of progression from a Japan-based medical-electronics manufacturer to an international in-vitro diagnostics group built around automation, recurring reagent use, service relationships, and laboratory integration.

• 2008

  Corporate name changed to Sysmex Corporation

  TOA Medical Electronics adopted the Sysmex Corporation name, formalizing the international brand identity used across its diagnostic businesses.

• 1968

  Company established as TOA Medical Electronics

  The Japanese medical-electronics company that later became Sysmex was established, beginning the business that would develop into a major clinical-laboratory diagnostics supplier.

• Global expansion of the diagnostic portfolio

  Across subsequent decades, the company expanded from hematology into urinalysis, hemostasis, flow cytometry, automation, information systems, and specialized laboratory diagnostics.

• Strategic laboratory-diagnostics alliance with Siemens Healthineers

  Sysmex entered a global strategic relationship with Siemens Healthineers to provide complementary laboratory-diagnostics capabilities in selected markets.

• Expansion in specialized hemostasis through HYPHEN BioMed

  Sysmex acquired HYPHEN BioMed, strengthening its portfolio of specialized hemostasis products and expertise.

A premium, technology-led global in-vitro diagnostics supplier focused on reliable automated testing, laboratory workflow integration, reagent-and-instrument ecosystems, and long-term clinical-laboratory partnerships.

• Hematology

  XN-Series hematology analyzers

  The XN series is a family of automated hematology analyzers for routine blood-cell testing and more advanced cellular analysis. Depending on configuration, systems support complete blood counts, differential analysis, flags for abnormal populations, and specialized measurements. They are designed for laboratories seeking scalable throughput, standardized operation, and integration with reagents, automation, and laboratory information systems.

• Urinalysis

  UF-Series urinalysis systems

  The UF family comprises automated systems for urine-particle and sediment analysis. By applying standardized instrument-based measurement to a field traditionally dependent on manual microscopy, these systems can help laboratories improve consistency and process larger sample volumes. The family is part of Sysmex’s broader urinalysis offering, which also includes related chemistry and workflow components in appropriate markets.

• Hemostasis and coagulation

  CS-Series hemostasis analyzers

  The CS series is a range of automated hemostasis analyzers used for coagulation and related laboratory testing. The systems are intended for routine and specialized work in hospital and reference laboratories, with emphasis on automation, reproducibility, sample handling, and connectivity. They operate within an ecosystem of compatible reagents, quality-control materials, software, and service support.

• Laboratory automation

  Laboratory automation systems

  Sysmex provides automation technologies that connect specimen reception, transport, analysis, sorting, and other laboratory steps. These systems are intended to reduce manual handling, improve traceability, increase throughput, and coordinate multiple analyzers. Automation can be configured for different laboratory sizes and disciplines and is frequently combined with middleware, information systems, and ongoing technical support.

• Laboratory software

  Laboratory information and middleware solutions

  Sysmex’s software and connectivity offerings support instrument integration, workflow management, result handling, quality oversight, and communication with laboratory information environments. These tools help laboratories coordinate analyzers and automation while improving visibility into specimen status and testing operations. They are an important part of the company’s move from individual instruments toward connected laboratory ecosystems.

• 2008

  Adoption of the Sysmex corporate nameStrategy

  Background

  The international Sysmex brand had become more prominent than the original TOA Medical Electronics corporate name as the company expanded its diagnostic operations globally.

  Action taken

  The company changed its legal corporate name to Sysmex Corporation.

  Aftermath

  The change unified the corporate and commercial identities used across the group’s international in-vitro diagnostics businesses.

• 2021-06-20

  Sysmex launches HISCL-5000 analyzer and SARS-CoV-2 antigen assay in EMEA[1]Sysmex在欧洲、中东和非洲地区推出HISCL-5000分析仪及新冠抗原检测试剂盒selectscience.net

  Sysmex Europe announced the launch in EMEA of the HISCL-5000 fully automated immunochemistry analyzer and the HISCL SARS-CoV-2 Ag Assay Kit.

• 2020-12-14

  Roche and Sysmex renew global partnership[2]Roche与Sysmex续签全球合作协议finanznachrichten.de

  Reported: 2021-01-25

  Roche and Sysmex signed a global business partnership agreement on December 14, 2020, renewing their distribution, sales and service agreement and introducing an IT solutions collaboration agreement. The agreement runs through the end of 2030.

1. 1Sysmex在欧洲、中东和非洲地区推出HISCL-5000分析仪及新冠抗原检测试剂盒selectscience.net
2. 2Roche与Sysmex续签全球合作协议finanznachrichten.de